James R. Empfield Acquires 10,000 Shares of Xenon Pharmaceuticals Inc. (XENE) Stock
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) SVP James R. Empfield acquired 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The stock was acquired at an average cost of $2.48 per share, with a total value of $24,800.00. Following the completion of the acquisition, the senior vice president now directly owns 10,000 shares in the company, valued at $24,800. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Xenon Pharmaceuticals Inc. (XENE) traded up 5.66% during midday trading on Thursday, reaching $2.80. The company’s stock had a trading volume of 56,147 shares. The stock’s market capitalization is $50.39 million. Xenon Pharmaceuticals Inc. has a 52-week low of $2.25 and a 52-week high of $9.95. The firm has a 50-day moving average price of $3.13 and a 200 day moving average price of $4.94.
Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.03. Xenon Pharmaceuticals had a negative net margin of 3,489.63% and a negative return on equity of 47.53%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.38 million. Equities research analysts predict that Xenon Pharmaceuticals Inc. will post ($0.96) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/17/james-r-empfield-acquires-10000-shares-of-xenon-pharmaceuticals-inc-xene-stock.html.
A number of hedge funds have recently added to or reduced their stakes in XENE. DAFNA Capital Management LLC raised its stake in Xenon Pharmaceuticals by 11.2% in the second quarter. DAFNA Capital Management LLC now owns 377,695 shares of the biopharmaceutical company’s stock worth $1,190,000 after buying an additional 38,081 shares in the last quarter. Endurant Capital Management LP acquired a new stake in Xenon Pharmaceuticals during the first quarter worth approximately $1,363,000. Sabby Management LLC acquired a new stake in Xenon Pharmaceuticals during the first quarter worth approximately $1,186,000. Renaissance Technologies LLC raised its stake in Xenon Pharmaceuticals by 90.1% in the first quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock worth $868,000 after buying an additional 102,890 shares in the last quarter. Finally, K2 Principal Fund L.P. raised its stake in Xenon Pharmaceuticals by 40.6% in the second quarter. K2 Principal Fund L.P. now owns 164,510 shares of the biopharmaceutical company’s stock worth $518,000 after buying an additional 47,535 shares in the last quarter. 56.01% of the stock is owned by hedge funds and other institutional investors.
XENE has been the subject of a number of recent analyst reports. Zacks Investment Research lowered Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. Jefferies Group LLC restated a “buy” rating and issued a $8.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, June 12th. Finally, Canaccord Genuity restated a “buy” rating and issued a $5.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, June 27th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $11.88.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.